![Florian Fischer](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Florian Fischer
Nessuna posizione attualmente
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Ulrich Grau | M | 75 | 9 anni | |
Thomas O. Hecht | M | 73 | 17 anni | |
Bernhard R. M. Ehmer | M | 69 | 8 anni | |
Mathieu Simon | M | 68 | 6 anni | |
Susanne Hering | F | - | 9 anni | |
Wolfgang Fischer | M | 60 | 7 anni | |
Denise Mueller | F | 55 | 8 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Adolf Hoess | M | 62 | 14 anni | |
Richard Stead | M | 71 | - | |
Anne Kerber | M | - | - | |
Caroline Y. Stewart | F | - | - | |
Berndt A. E. Modig | M | 65 | 6 anni | |
Ferdinand Verdonck | M | 81 | 7 anni | |
Gregory W. Gin | M | - | - | |
Eugene Zhukovsky | M | 65 |
Affimed NV Niederlassung Deutschland
![]() Affimed NV Niederlassung Deutschland Pharmaceuticals: MajorHealth Technology Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany. | 3 anni |
Roland Toder | M | - |
Vivendy Therapeutics Ltd.
![]() Vivendy Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland. | 2 anni |
Gertrud Thormann-Huber | M | - |
Vivendy Therapeutics Ltd.
![]() Vivendy Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland. | - |
Michael Wolf | M | - | - | |
Hans Paul Walliser | M | - |
Vivendy Therapeutics Ltd.
![]() Vivendy Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland. | - |
John Stuart Patton | M | 77 |
Vectura GmbH
![]() Vectura GmbH Medical SpecialtiesHealth Technology Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany. | 7 anni |
Jens Peter Marschner | M | 61 | - | |
Oscar Kashala | M | - | - | |
Andrew Curtis | M | - | - | |
Jöerg Windisch | M | 53 | 1 anni | |
Leila Alland | M | 61 | 1 anni | |
Anca Alexandru | M | - | - | |
Erich Rajkovic | M | - | - | |
Thomas Hofmann | M | - |
Vectura GmbH
![]() Vectura GmbH Medical SpecialtiesHealth Technology Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany. | 6 anni |
Arndt Rolfs | M | 64 |
Vivendy Therapeutics Ltd.
![]() Vivendy Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland. | - |
Martin Treder | M | - | 4 anni | |
Walter Dettling | M | - |
Vivendy Therapeutics Ltd.
![]() Vivendy Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland. | - |
Sergej M. Kiprijanov | M | - |
Affimed NV Niederlassung Deutschland
![]() Affimed NV Niederlassung Deutschland Pharmaceuticals: MajorHealth Technology Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany. | 6 anni |
Annegret de Baey-Diepolder | M | - |
Vivendy Therapeutics Ltd.
![]() Vivendy Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland. | - |
Volker Lang | M | 64 |
Affimed NV Niederlassung Deutschland
![]() Affimed NV Niederlassung Deutschland Pharmaceuticals: MajorHealth Technology Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany. | - |
Frank Mühlenbeck | M | 53 |
Affimed NV Niederlassung Deutschland
![]() Affimed NV Niederlassung Deutschland Pharmaceuticals: MajorHealth Technology Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany. | - |
Gerhard Ries | M | 55 |
Vivendy Therapeutics Ltd.
![]() Vivendy Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland. | - |
Miroslav S. Ravic | M | 75 |
Affimed NV Niederlassung Deutschland
![]() Affimed NV Niederlassung Deutschland Pharmaceuticals: MajorHealth Technology Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany. | - |
Jörg Neermann | M | 57 |
Vivendy Therapeutics Ltd.
![]() Vivendy Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland. | - |
Domenico Valerio | M | 67 |
Vivendy Therapeutics Ltd.
![]() Vivendy Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland. | - |
Gosse Bote Bruinsma | M | 69 |
Vivendy Therapeutics Ltd.
![]() Vivendy Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland. | - |
Cassandra Choe-Juliak | M | - | - |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Germania | 31 | 75.61% |
Svizzera | 10 | 24.39% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Florian Fischer
- Contatti personali